uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Exploring the epigenetic drug discovery landscape
Mahidol Univ, Fac Med Technol, Ctr Data Min & Biomed Informat, Bangkok, Thailand..
Natl Inst Biomed Innovat, Osaka, Japan.;Natl Inst Hlth & Nutr, Osaka, Japan..
Mahidol Univ, Fac Med Technol, Ctr Data Min & Biomed Informat, Bangkok, Thailand..
Mahidol Univ, Fac Med Technol, Ctr Data Min & Biomed Informat, Bangkok, Thailand..
Show others and affiliations
2017 (English)In: Expert Opinion on Drug Discovery, ISSN 1746-0441, E-ISSN 1746-045X, Vol. 12, no 4, 345-362 p.Article, review/survey (Refereed) Published
Abstract [en]

Introduction: Epigenetic modification has been implicated in a wide range of diseases and the ability to modulate such systems is a lucrative therapeutic strategy in drug discovery. Areas covered: This article focuses on the concepts and drug discovery aspects of epigenomics. This is achieved by providing a survey of the following concepts: (i) factors influencing epigenetics, (ii) diseases arising from epigenetics, (iii) epigenetic enzymes as druggable targets along with coverage of existing FDA-approved drugs and pharmacological agents, and (iv) drug repurposing/repositioning as a means for rapid discovery of pharmacological agents targeting epigenetics. Expert opinion: Despite significant interests in targeting epigenetic modifiers as a therapeutic route, certain classes of target proteins are heavily studied while some are less characterized. Thus, such orphan target proteins are not yet druggable with limited report of active modulators. Current research points towards a great future with novel drugs directed to the many complex multifactorial diseases of humans, which are still often poorly understood and difficult to treat.

Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD , 2017. Vol. 12, no 4, 345-362 p.
Keyword [en]
Epigenomics, epigenetics, drug discovery, drugs, bioinformatics, cheminformatics, chemogenomics, proteochemometrics
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:uu:diva-321031DOI: 10.1080/17460441.2017.1295954ISI: 000396838300004PubMedID: 28276705OAI: oai:DiVA.org:uu-321031DiVA: diva2:1091834
Funder
Swedish Research Council, C0610701
Available from: 2017-04-28 Created: 2017-04-28 Last updated: 2017-04-28Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Wikberg, Jarl E. S.
By organisation
Department of Pharmaceutical Biosciences
In the same journal
Expert Opinion on Drug Discovery
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 10 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf